Results 161 to 170 of about 8,618 (210)
Some of the next articles are maybe not open access.
IL33 and sST2 serum level in systemic sclerosis microvascular involvement
Microvascular Research, 2022Endothelial dysfunction and microvascular damage are hallmarks of systemic sclerosis (SSc). Objective of this study was to evaluate IL33 and ST2 serum levels in SSc patients and healthy controls (HC). Secondary aim was to evaluate the IL33 axis in the SSc microvascular manifestation.IL33 and sST2 have been assessed in 46 SSc patients and 24 HC matched ...
Pellicano C. +3 more
openaire +4 more sources
ESC Heart Failure, 2022 To define plasma concentrations, determinants, and optimal prognostic cut‐offs of soluble suppression of tumorigenesis‐2 (sST2), high‐sensitivity cardiac troponin T (hs‐cTnT), and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) in women and men ...
Giuseppe Vergaro +2 more
exaly +2 more sources
Alarmins (IL-33, sST2, HMGB1, and S100B) as potential biomarkers for schizophrenia
Journal of Psychiatric Research, 2021 There is growing evidence that immune/inflammatory processes are related to the etiology of schizophrenia. Danger-/damage-associated molecular patterns (DAMPs), also called alarmins, are recognized as inflammatory mediators that play an important role in
Ewa Brzezińska-Błaszczyk +2 more
exaly +2 more sources
sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T
Journal of the American College of Cardiology, 2018 BACKGROUND Soluble suppression of tumorigenesis-2 (sST2) is a biomarker related to inflammation and fibrosis. OBJECTIVES This study assessed the independent prognostic value of sST2 in chronic heart failure (HF).
Michele Emdin +2 more
exaly +2 more sources
Journal of Clinical Medicine, 2019 Soluble ST2 (sST2) has recently emerged as a promising biomarker in the field of acute cardiovascular diseases. Several clinical studies have demonstrated a significant link between sST2 values and patients’ outcome.
Aneta Aleksova +2 more
exaly +2 more sources
Characterisation of somatostatin sst2 receptor splice variants
Journal of Physiology-Paris, 2000Somatostatin is a peptide with a multitude of functions in the central nervous system and the periphery. It mediates its actions by binding to high-affinity G-protein coupled receptors, genes for five of which (sst1-sst5) have recently been cloned. The somatostatin sst2 receptor exists as two splice variants, sst2(a) and sst2(b) receptors, which differ
S L, Cole, M, Schindler
openaire +2 more sources
ESC Heart Failure, 2020 Inflammation and cardiac remodelling are common and synergistic pathways in heart failure (HF). Emerging biomarkers such as soluble suppression of tumorigenicity 2 (sST2) and growth differentiation factor‐15 (GDF‐15), which are linked to inflammation and
Fabien Huet +2 more
exaly +2 more sources
Clinical relevance of sST2 in cardiac diseases
Clinical Chemistry and Laboratory Medicine (CCLM), 2016AbstractST2 has two main isoforms, ST2L and soluble isoform of ST2 (sST2), by alternative splicing. The interaction between interleukin (IL)-33 and the transmembrane isoform ST2L is up-regulated in response to myocardial stress and exerts cardio-protective actions in the myocardium by reducing fibrosis, hypertrophy and enhancing survival.
Domingo A. Pascual-Figal +5 more
openaire +2 more sources
International Journal of Cardiology, 2020
BACKGROUNDS Prognostic value of soluble suppression of tumorigenecity (sST2), a novel circulating biomarker for myocardial fibrosis, remains elusive in the heart failure patients with preserved ejection fraction (HFpEF).
Yuan Liu, Yanyan Wang, Xueting Han
exaly +2 more sources
BACKGROUNDS Prognostic value of soluble suppression of tumorigenecity (sST2), a novel circulating biomarker for myocardial fibrosis, remains elusive in the heart failure patients with preserved ejection fraction (HFpEF).
Yuan Liu, Yanyan Wang, Xueting Han
exaly +2 more sources